Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow-to-Debt Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. cash flow-to-debt ratio. Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow-to-Debt Ratio of 0.08x as of September 2025, meaning its operating cash flow of CN¥11.57 Million could theoretically repay 0% of its total liabilities (CN¥142.19 Million) in one year. Check 301211 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
Cash flow-to-debt ratio of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025. Historical debt coverage capacity for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 9 annual periods. Check cash flow reinvestment rate of Hubei Biocause Heilen Pharmaceutical Co. to assess the company's total reinvestment commitment from operating cash flow.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow-to-Debt Ratio by Year (2017–2025)
Hubei Biocause Heilen Pharmaceutical Co. Ltd. cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. For the full cash flow conversion analysis, see Hubei Biocause Heilen Pharmaceutical Co. operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | CN¥7.55 Million | CN¥128.65 Million | ▼ -89.1% |
| 2024 | 0.54x | CN¥96.07 Million | CN¥178.97 Million | ▼ -25.6% |
| 2023 | 0.72x | CN¥137.06 Million | CN¥189.89 Million | ▼ -36.3% |
| 2022 | 1.13x | CN¥250.79 Million | CN¥221.22 Million | ▼ -1.7% |
| 2021 | 1.15x | CN¥123.98 Million | CN¥107.53 Million | ▼ -2.5% |
| 2020 | 1.18x | CN¥121.67 Million | CN¥102.85 Million | ▼ -18.2% |
| 2019 | 1.45x | CN¥372.33 Million | CN¥257.31 Million | ▲ +356.5% |
| 2018 | 0.32x | CN¥76.18 Million | CN¥240.36 Million | ▲ +210.1% |
| 2017 | -0.29x | CN¥-65.44 Million | CN¥227.25 Million | — |